Please provide your email address to receive an email when new articles are posted on . As the combination of bumetanide and chlorthalidone reduced arterial pressure and volume overload in patients ...
Tirzepatide significantly reduces cardiovascular death or worsening heart failure risk by 38% in patients with obesity-related HFpEF. The drug improves blood pressure, inflammation, and volume ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback